Article in Journal of Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07288450 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Terazosin And Metabolic Engagement in Parkinson's Disease
TypeinterventionalSponsorNandakumar NarayananRan2026 to 2031Enrolled100ConditionsParkinson's DiseaseArmsTerazosin Hydrochloride, Placebo
NCT07464028 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
TypeinterventionalSponsorNandakumar NarayananRan2026 to 2031Enrolled120ConditionsParkinson's Disease (PD)ArmsTerazosin 5 MG, Placebo
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Jordan L SchultzDepartment of Psychiatry, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-0985-7268
Phillip E GanderDepartment of Radiology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-3945-8820
Craig D WorkmanDepartment of Radiology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0001-8360-0199
Laura L Boles PontoDepartment of Radiology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-1197-6714
Stephen CrossDepartment of Psychiatry, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Christopher S NanceDepartment of Neurology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-3803-2940
Christopher L GrothDepartment of Neurology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-6228-0824
Eric B TaylorDepartment of Molecular Physiology and Biophysics, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-4549-6567
Sarah E ErnstPappajohn Biomedical Institute, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Jia XuDepartment of Radiology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-0189-5833
Ergun Y UcDepartment of Neurology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-4430-6960
Vincent A MagnottaDepartment of Radiology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0001-8639-5354
Michael J WelshDepartment of Neurology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-1646-6206
Nandakumar S NarayananDepartment of Neurology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-0427-0003
Funding
The University of Iowa Clinical and Translational Science AwardUL1TR002537 · NCATS · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R, WINOKUR, PATRICIA · 2018 to 2022
$20.0M
University of Iowam - Whole Body 7T MRI ScannerS10RR028821 · NCRR · UNIVERSITY OF IOWA · PI MAGNOTTA, VINCENT A · 2010 to 2010
$8.0M
Investigating Autonomic Dysfunction as an Early Pathologic Feature of Huntington’s DiseaseK23NS117736 · NINDS · UNIVERSITY OF IOWA · PI SCHULTZ, JORDAN · 2021 to 2025
BackgroundParkinson's disease (PD) is a common neurodegenerative disease lacking treatments that modify progressive neuron loss. Terazosin (TZ) increases activity of the glycolytic enzyme phosphoglycerate kinase 1 and could potentially benefit impaired brain bioenergetics in PD. Preclinical data are encouraging, but we lack human data on relationships between TZ dose and measures of TZ target engagement in women and men.ObjectiveThis study evaluated the dose-dependent effects of TZ on brain and systemic bioenergetics and safety and tolerability in neurologically healthy older adults.MethodsWe administered TZ (1, 5, and 10 mg/day) to 18 neurologically healthy 60-85-year-old people. We measured plasma and cerebrospinal fluid TZ concentrations and changes in levels of whole blood ATP, brain ATP with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. · full record | OpenQuestion